Cargando…
Reimbursement of orphan drugs in Belgium: what (else) matters?
BACKGROUND: Most orphan drugs do not meet traditional standards of cost-effectiveness. Yet, most orphan drugs are reimbursed, which implies that other factors are taken into account at the time of reimbursement. To increase accountability of decision-makers, there is a need for more transparency in...
Autores principales: | Picavet, Eline, Cassiman, David, Simoens, Steven |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4172832/ https://www.ncbi.nlm.nih.gov/pubmed/25208770 http://dx.doi.org/10.1186/s13023-014-0139-z |
Ejemplares similares
-
Shining a light in the black box of orphan drug pricing
por: Picavet, Eline, et al.
Publicado: (2014) -
Development and validation of COMPASS: clinical evidence of orphan medicinal products – an assessment tool
por: Picavet, Eline, et al.
Publicado: (2013) -
Clinical evidence for orphan medicinal products-a cause for concern?
por: Picavet, Eline, et al.
Publicado: (2013) -
Pricing and reimbursement of orphan drugs: the need for more transparency
por: Simoens, Steven
Publicado: (2011) -
Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
por: Stawowczyk, Ewa, et al.
Publicado: (2019)